Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancerMEILIN LIAO; HUIMIN WANG; ZHENQIONG LIN et al.Lung cancer. 2001, Vol 33, Num 2-3, pp 125-132, issn 0169-5002Article

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell linesLAN SHEN; ZIMING LI; SHENGPINGSHEN et al.Lung cancer. 2012, Vol 78, Num 3, pp 193-200, issn 0169-5002, 8 p.Article

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective studyLI ZHANG; XUE HOU; MEILIN LIAO et al.Lung cancer. 2010, Vol 67, Num 1, pp 114-119, issn 0169-5002, 6 p.Article

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung CancerMOK, Tony S. K; WU, Yi-Long; CHUA-TAN, Marina et al.Journal of clinical oncology. 2009, Vol 27, Num 30, pp 5080-5087, issn 0732-183X, 8 p.Article

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non―Small-Cell Lung CancerPAZ-ARES, Luis G; BIESMA, Bonne; SYRIGOS, Kostas et al.Journal of clinical oncology. 2012, Vol 30, Num 25, pp 3084-3092, issn 0732-183X, 9 p.Article